Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7

This publication has 31 references indexed in Scilit:

• Persistent human papillomavirus infection and cervical neoplasia
  The Lancet Oncology, 2002
• Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7
  Gene Therapy, 2002
• Cancer burden in the year 2000. The global picture
  Published by Elsevier ,2001
• The Potency and Durability of DNA- and Protein-Based Vaccines Against Leishmania major Evaluated Using Low-Dose, Intradermal Challenge
  The Journal of Immunology, 2001
• Revealing the Potential of DNA-Based Vaccination: Lessons Learned from the Hepatitis B Virus Surface Antigen
  Biological Chemistry, 2001
• Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7
  Gene Therapy, 2000
• Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia
  International Journal of Cancer, 2000
• Recombinant viruses as a tool for therapeutic vaccination against human cancers
  Immunology Letters, 2000
• Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
  European Journal of Immunology, 1993
• A New Generation of Animal Cell Expression Vectors Based on the Semliki Forest Virus Replicon
  Bio/Technology, 1991